Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: A prospective study on patients with HCV related cirrhosis

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 21

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

521

HTML

2149

Figures (1-5)

152

Tables (1-1)

135

Sum=2957

Nov 1, 2004 (publication date) through Apr 30, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Liver Cancer

World J Gastroenterol. Nov 1, 2004; 10(21): 3099-3102
Published online Nov 1, 2004. doi: 10.3748/wjg.v10.i21.3099

Figure 1 Study design.

Open in New Tab Full Size Figure Download Figure

Figure 2 AgNOR-PI in OTCG before and after 1 year of IFN treatment.

Figure 3 Incidence of HCC according to AgNOR-PI.

Figure 4 Percentage of HCC according to response to IFN.

Figure 5 Survival probability evaluated by Kaplan-Mayer model.

Citation: Francesco A, Esterita A, Giovanni N, Davide T, Silvia G, Anna M, Francesca L, Marco M, Mariarosa T, Antonio C, Constance M, Davide F, Enrico R, Massimo D, Giuseppe M. Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: A prospective study on patients with HCV related cirrhosis. World J Gastroenterol 2004; 10(21): 3099-3102
URL: https://www.wjgnet.com/1007-9327/full/v10/i21/3099.htm
DOI: https://dx.doi.org/10.3748/wjg.v10.i21.3099